AU2015246030B2 - Composition and method of producing nanoformulation of water insoluble bioactives in aqueous base - Google Patents

Composition and method of producing nanoformulation of water insoluble bioactives in aqueous base Download PDF

Info

Publication number
AU2015246030B2
AU2015246030B2 AU2015246030A AU2015246030A AU2015246030B2 AU 2015246030 B2 AU2015246030 B2 AU 2015246030B2 AU 2015246030 A AU2015246030 A AU 2015246030A AU 2015246030 A AU2015246030 A AU 2015246030A AU 2015246030 B2 AU2015246030 B2 AU 2015246030B2
Authority
AU
Australia
Prior art keywords
nanodispersion
predetermined quantity
stabilizer
nsvbc
aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015246030A
Other languages
English (en)
Other versions
AU2015246030A1 (en
Inventor
Pranati CHHATOI
Krishna Kaushik CHINTABHATLA
Anand Vasant DESHMUKH
Rambhau Devraj
Naga Hemanth Kumar PARVATHABHATLA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pulse Pharmaceuticals Pvt Ltd
Original Assignee
Pulse Pharmaceuticals Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulse Pharmaceuticals Pvt Ltd filed Critical Pulse Pharmaceuticals Pvt Ltd
Publication of AU2015246030A1 publication Critical patent/AU2015246030A1/en
Application granted granted Critical
Publication of AU2015246030B2 publication Critical patent/AU2015246030B2/en
Assigned to PULSE PHARMACEUTICALS PVT LTD reassignment PULSE PHARMACEUTICALS PVT LTD Request for Assignment Assignors: NANOCEUTICA LABORATORIES PVT. LTD
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Colloid Chemistry (AREA)
AU2015246030A 2014-04-09 2015-04-08 Composition and method of producing nanoformulation of water insoluble bioactives in aqueous base Active AU2015246030B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1872/CHE/2014 2014-04-09
PCT/IB2015/052541 WO2015155703A2 (en) 2014-04-09 2015-04-08 Composition and method of producing nanoformulation of water insoluble bioactives in aqueous base
IN1872CH2014 IN2014CH01872A (enExample) 2014-04-09 2015-04-08

Publications (2)

Publication Number Publication Date
AU2015246030A1 AU2015246030A1 (en) 2016-11-24
AU2015246030B2 true AU2015246030B2 (en) 2020-03-12

Family

ID=54288490

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015246030A Active AU2015246030B2 (en) 2014-04-09 2015-04-08 Composition and method of producing nanoformulation of water insoluble bioactives in aqueous base

Country Status (7)

Country Link
US (1) US11458096B2 (enExample)
EP (1) EP3129002A4 (enExample)
AU (1) AU2015246030B2 (enExample)
EA (1) EA038458B1 (enExample)
IN (1) IN2014CH01872A (enExample)
MX (1) MX2016013201A (enExample)
WO (1) WO2015155703A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6825913B2 (ja) 2014-04-30 2021-02-03 マトケ・ホールディングス・リミテッド 抗菌組成物
GB201716986D0 (en) 2017-10-16 2017-11-29 Matoke Holdings Ltd Antimicrobial compositions
FR3075661A1 (fr) * 2017-12-21 2019-06-28 Coatex Emulsion submicronique
WO2019133785A1 (en) * 2017-12-29 2019-07-04 L'oreal Compositions for altering the color of hair
WO2019175830A1 (en) * 2018-03-14 2019-09-19 Azista Industries Pvt Ltd Cholecalciferol nanoemulsion formulations and methods for producing same
WO2023118928A1 (en) 2021-12-21 2023-06-29 Opella Healthcare Group Sas Stable nanoformulation for lipophilic actives, oral dosage form and process for its preparation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010814A1 (en) * 1995-09-18 1997-03-27 Vesifact Ag Propofol nanodispersions
WO2003077882A2 (en) * 2002-03-18 2003-09-25 Labopharm Inc. Preparation of sterile stabilized nanodispersions
WO2010146606A1 (en) * 2009-06-19 2010-12-23 Sun Pharma Advanced Research Company Ltd., Nanodispersion of a drug and process for its preparation
WO2011075623A1 (en) * 2009-12-18 2011-06-23 Latitude Pharmaceuticals, Inc. One - phase gel compos ition compri s ing phos pholi pids

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2108266C (en) * 1991-04-19 2003-06-03 Albert J. Owen Convertible microemulsion formulations
CA2091152C (en) 1993-03-05 2005-05-03 Kirsten Westesen Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
DE19642359A1 (de) 1996-10-14 1998-04-16 Basf Ag Stabile Emulsionen und Trockenpulver von Mischungen fettlöslicher Vitamine, deren Herstellung und Verwendung
US5994414A (en) 1997-04-28 1999-11-30 Avon Products, Inc. Water-thin emulsion formed by high pressure homogenization process
DE50100901D1 (de) * 2001-04-12 2003-12-11 Vesifact Ag Baar Coenzym Q10 enthaltende Mikroemulsion-Prekonzentrate und Mikroemulsionen
AU2003238221A1 (en) 2002-06-17 2003-12-31 Taro Pharmaceuticals U.S.A, Inc. Ibuprofen suspension
US8628690B2 (en) 2004-02-23 2014-01-14 The Texas A&M University System Nanoemulsion compositions and methods of use thereof
EP1597973A1 (en) 2004-05-18 2005-11-23 Nestec S.A. Oil-in-water emulsion for delivery
US20060051462A1 (en) * 2004-09-03 2006-03-09 Wang Jimmy X Self emulsifying compositions for delivering lipophilic coenzyme Q10 and other dietary ingredients
EP1959994B1 (en) 2005-12-01 2017-08-30 University Of Massachusetts Lowell Botulinum nanoemulsions
CN101011355B (zh) * 2006-02-01 2013-01-02 陈献 经维生素e琥珀酸酯稳定的医药组合物、其制备及用途
AU2007224006A1 (en) 2006-03-07 2007-09-13 Novavax, Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
EP1938801A1 (en) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
EP2225275A4 (en) * 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
EP2222340B1 (en) 2007-11-28 2014-01-08 Commonwealth Scientific and Industrial Research Organisation Nanoemulsions
US20100158998A1 (en) 2008-12-23 2010-06-24 Michael Fox Formulations comprising vitamin d or derivatives thereof
AU2010222648B2 (en) 2009-03-09 2016-07-07 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
WO2010133609A2 (en) * 2009-05-18 2010-11-25 Sigmoid Pharma Limited Composition comprising oil drops
EP3366280A1 (en) * 2010-03-12 2018-08-29 Berg LLC Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
US20110229516A1 (en) * 2010-03-18 2011-09-22 The Clorox Company Adjuvant phase inversion concentrated nanoemulsion compositions
SE536746C2 (sv) 2010-05-12 2014-07-08 Stora Enso Oyj En komposition innehållande mikrofibrillerad cellulosa och en process för tillverkning av en komposition
US8835509B2 (en) 2010-05-31 2014-09-16 Arbro Pharmaceuticals Ltd. Self emulsifying drug delivery system for a curcuminoid based composition
WO2012032415A2 (en) 2010-09-08 2012-03-15 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin
WO2013008083A1 (en) 2011-07-13 2013-01-17 National Institute Of Pharmaceutical Education And Research (Niper) Pharmaceutical composition for enhancing anticancer efficacy of tamoxifen
NZ596015A (en) 2011-10-26 2014-04-30 Anzamed Internat Ltd Method and composition for the treatment of pain and/or inflammation
GB201204377D0 (en) 2012-03-13 2012-04-25 Givaudan Sa Composition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010814A1 (en) * 1995-09-18 1997-03-27 Vesifact Ag Propofol nanodispersions
WO2003077882A2 (en) * 2002-03-18 2003-09-25 Labopharm Inc. Preparation of sterile stabilized nanodispersions
WO2010146606A1 (en) * 2009-06-19 2010-12-23 Sun Pharma Advanced Research Company Ltd., Nanodispersion of a drug and process for its preparation
WO2011075623A1 (en) * 2009-12-18 2011-06-23 Latitude Pharmaceuticals, Inc. One - phase gel compos ition compri s ing phos pholi pids

Also Published As

Publication number Publication date
EA038458B1 (ru) 2021-08-31
EP3129002A4 (en) 2017-11-08
EA201692044A1 (ru) 2017-04-28
EP3129002A2 (en) 2017-02-15
MX2016013201A (es) 2017-04-25
IN2014CH01872A (enExample) 2015-05-08
AU2015246030A1 (en) 2016-11-24
WO2015155703A3 (en) 2015-12-30
WO2015155703A2 (en) 2015-10-15
US20180177723A1 (en) 2018-06-28
US11458096B2 (en) 2022-10-04

Similar Documents

Publication Publication Date Title
AU2015246030B2 (en) Composition and method of producing nanoformulation of water insoluble bioactives in aqueous base
US20220257510A1 (en) Compositions for Nanoemulsion Delivery Systems
EP3159012B1 (en) Nanoemulsions having reversible continuous and dispersed phases
US20220241217A1 (en) Compositions for the delivery of therapeutic agents and methods of use and making thereof
Li et al. In vitro and in vivo evaluation of a simple microemulsion formulation for propofol
CN102341166B (zh) 分散组合物及分散组合物的制造方法
JP5603852B2 (ja) 凍結乾燥ナノエマルション
JPH02290809A (ja) 水中油型乳液の形態にある疎水性薬剤の製薬学的組成物
Lixin et al. A less irritant norcantharidin lipid microspheres: formulation and drug distribution
KR20040018432A (ko) 약물 내포 고분자 미셀의 동결 건조용 조성물 또는 미셀의제조방법
RS60119B1 (sr) Poboljšane formulacije levosimendana za intravensko davanje kao infuzija ili injekcija i infuzioni koncentrat
Gehrmann et al. Preparation of lipid nanoemulsions by premix membrane emulsification with disposable materials
Su et al. Solubility enhancement and antioxidation maintenance of CBD encapsulated in the P407-RUB nano-micelle system
US20240009122A1 (en) Small Molecule Formulation
Mao et al. Emulsifiers’ composition modulates venous irritation of the nanoemulsions as a lipophilic and venous irritant drug delivery system
JP2013018737A (ja) 凍結乾燥製剤及びその製造方法
US20240261219A1 (en) New oil-in-water nanoemulsion
Setiawan et al. Formulation of self nano-emulsifying drug delivery system (SNEDDS) loaded red fruit oil (Pandanus conoideus Lamk.) using biodegradable nutraceutical surfactant
KR20010055736A (ko) 프로포폴의 마이크로에멀젼 주사제 조성물
HK1233192B (en) Nanoemulsions having reversible continuous and dispersed phases
Mansukmanee et al. Silpakorn University, Nakhon Pathom 73000 Thailand, Phone:+ 66 34 255800, Fax: 17+ 66 34 255801, E-mail: pornsak@ su. ac. th 18
HK1233192A1 (en) Nanoemulsions having reversible continuous and dispersed phases
CN101703462A (zh) 冬凌草乙素高度分散制剂

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: PULSE PHARMACEUTICALS PVT LTD

Free format text: FORMER APPLICANT(S): NANOCEUTICA LABORATORIES PVT. LTD

FGA Letters patent sealed or granted (standard patent)